Dr. John Carpten is the Director of City of Hope’s National Cancer Institute-designated Comprehensive Cancer Center, Director of Beckman Research Institute of City of Hope, and Chief Scientific Officer. He also holds the Irell & Manella Cancer Center Director’s Distinguished Chair and the Morgan & Helen Chu Director’s Chair of the Beckman Research Institute. Dr. Carpten provides overall executive leadership and strategic direction for research at City of Hope.
An internationally recognized expert in genome science, Dr. Carpten has deep experience in multiple disciplines, including germline genetics for disease risk and predisposition, somatic cancer genomics, health disparities research, cell biology, functional genomics, and precision medicine. In 2022, President Joe Biden appointed Dr. Carpten as the first African American Chair of the National Institutes of Health’s National Cancer Advisory Board, a distinguished post that helps set the national cancer research policy agenda.
Dr. Carpten is uniquely positioned to help further City of Hope’s critical goal of democratizing cancer care and expanding access to leading-edge research and care for more patients, families and communities. He has been a national leader in health disparities research and has been a tireless advocate and key voice for reaching underserved populations, ending disparities in cancer outcomes and care, and building a more diverse workforce in cancer research.
Dr. Carpten joined City of Hope from the University of Southern California (USC), where he was professor and Chair of the Department of Translational Genomics at Keck School of Medicine of USC and Associate Director of the Cancer Center. Earlier in his career, he completed a postdoctoral fellowship at the National Human Genome Research Institute (part of the National Institutes of Health) in cancer genetics, where he was later promoted to the tenure track in 2000. Dr. Carpten earned his Ph.D. from The Ohio State University in 1994, with a focus on human genetics.
Sessions: